<DOC>
	<DOCNO>NCT02920190</DOCNO>
	<brief_summary>Background Antigen-driven selection implicate pathogenesis monoclonal gammopathy . Patients Gaucher 's disease increase risk monoclonal gammopathy symptomatic myeloma . Clonal immunoglobulin patient Gaucher 's disease mouse model Gaucher 's disease-associated gammopathy reactive lyso-glucosylceramide ( LGL1 ) , markedly elevate patient mouse . A recent report indicate clonal immunoglobulin 33 % sporadic human monoclonal gammopathy may also specific lysolipids LGL1 lysophosphatidylcholine . Substrate reduction ameliorate Gaucher 's disease-associated gammopathy mouse . This principle ( antigen removal induce tumor regression ) proven hematologic malignancy , H. Pylori eradication cause lymphoma regression significant group patient . Thus , longterm immune activation lysolipids may underlie Gaucher 's disease-associated gammopathy sporadic monoclonal gammopathy , may represent focus treatment . Epicardial fat ( EAT ) , visceral fat heart , highly enrich gene involve inflammation lipid metabolism ; activate local systemic inflammation innate inflammatory response . EAT rich saturate fatty acid high protein content , great capacity free fatty acid release uptake among visceral fat depot . Of interest , EAT highly enrich sphingolipids , include ceramide . EAT clinical measurability ultrasound technique , first develop validate Iacobellis , rapid responsiveness reduction medication target visceral fat , glucagon-like peptide 1 analogue ( GLP1A ) , ongoing clinical trial demonstrate , grow remarkable interest . Study Hypothesis To target EAT , marker visceral fat , GLP1A treatment modulate/reduce/remove antigen ( ) ( lipid/inflammatory/immune ) stimulation patient monoclonal gammopathy lipid target . Study Design Interventional , single-group , open label pilot study . The investigator identify monoclonal gammopathy patient whose antibody lipid/visceral fat target ( goal 10 initially pilot ) overweight/obese ( BMI &gt; 27 ) . Eligible patient start Liraglutide 1.8 mg sc daily , adjunct weight loss treatment 12 month . Study Endpoints - Ultrasound measure EAT reduction least 20 % - Improvement monoclonal immunoglobulin profile Reduction plasma ceramide lipidomics level Parameters monitor 3 month , 6 month 12 month .</brief_summary>
	<brief_title>Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>BMI ≥27 kg/m2 At least one overweight/obesity relate comorbidity ( type 2 diabetes , prediabetes [ IFG , IGT ] , hypertension , dyslipidemia ) Age &gt; 18 &lt; 70 year old Known contraindication Liraglutide , previous history pancreatitis medullary thyroid carcinoma , personal family history MEN , accordance risk safety information include late updated Prescribing Information Victoza® Type 1 diabetes , define American Diabetes Association ( ADA ) criteria Insulin dependent treat type 2 diabetes Current use injectable incretins History diabetes ketoacidosis Advanced Chronic Kidney Disease , define Glomerular Filtration Rate ( GFR ) &lt; 30 mL/min/1.73m2 Clinical sign symptoms New York Heart Association ( NYHA ) class IIIIV heart failure Clinical laboratory evidence chronic active liver disease Acute chronic infective disease Known suspect allergy Liraglutide , excipients , relate product Pregnant , breastfeed intention become pregnant Females childbearing potential use adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>